These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33290761)

  • 1. Advances in biological therapies for dyslipidemias and atherosclerosis.
    Valanti EK; Dalakoura-Karagkouni K; Siasos G; Kardassis D; Eliopoulos AG; Sanoudou D
    Metabolism; 2021 Mar; 116():154461. PubMed ID: 33290761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis.
    Mäkinen PI; Ylä-Herttuala S
    Curr Opin Lipidol; 2013 Apr; 24(2):116-22. PubMed ID: 23314926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biotherapies: a revolution on the move].
    Braun S
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():8-12. PubMed ID: 30943153
    [No Abstract]   [Full Text] [Related]  

  • 4. NEW BIOTECHNOLOGICAL TREATMENTS FOR LIPID DISORDERS.
    Valencia-Enciso N; Mendivil CO
    Rev Invest Clin; 2018; 70(5):244-254. PubMed ID: 30307447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
    Chadwick AC; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Delivery in Lipid Research and Therapies.
    De Giorgi M; Lagor WR
    Methodist Debakey Cardiovasc J; 2019; 15(1):62-69. PubMed ID: 31049151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides, microRNAs, and antibodies.
    Dávalos A; Chroni A
    Handb Exp Pharmacol; 2015; 224():649-89. PubMed ID: 25523006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Frontiers in the Therapeutic Approach of Patients with Cardiovascular and Endocrine Diseases.
    Grande D; Terlizzese P; Gioia MI; Parisi G; Giagulli VA; Triggiani V; Iacoviello M
    Endocr Metab Immune Disord Drug Targets; 2019; 19(5):605-621. PubMed ID: 30621568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy.
    Gaudet D; Drouin-Chartier JP; Couture P
    Can J Cardiol; 2017 Jul; 33(7):872-882. PubMed ID: 28365054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
    Larsen LE; Stoekenbroek RM; Kastelein JJP; Holleboom AG
    Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):349-359. PubMed ID: 30676072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the new frontiers in the treatment of atherogenic dyslipidemias.
    Rached FH; Chapman MJ; Kontush A
    Clin Pharmacol Ther; 2014 Jul; 96(1):57-63. PubMed ID: 24727469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Horizons: Novel Adrenal Regenerative Therapies.
    Bornstein SR; Malyukov M; Heller C; Ziegler CG; Ruiz-Babot G; Schedl A; Ludwig B; Steenblock C
    J Clin Endocrinol Metab; 2020 Sep; 105(9):3103-7. PubMed ID: 32629476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preface. What's New in Autoimmunity: New Autoantibodies, New Therapies, New Diseases.
    Lazzaroni MG; Nalli C; Tincani A
    Isr Med Assoc J; 2015 Feb; 17(2):71-3. PubMed ID: 26223080
    [No Abstract]   [Full Text] [Related]  

  • 14. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
    Stahel P; Xiao C; Hegele RA; Lewis GF
    Can J Cardiol; 2018 May; 34(5):595-604. PubMed ID: 29459241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing nucleic acid-based therapeutics for atherosclerotic cardiovascular disease: state of the art.
    Vahdat Lasemi F; Mahjoubin Tehran M; Aghaee-Bakhtiari SH; Jalili A; Jaafari MR; Sahebkar A
    Drug Discov Today; 2019 May; 24(5):1116-1131. PubMed ID: 30980904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in lipid-lowering therapy through gene-silencing technologies.
    Nordestgaard BG; Nicholls SJ; Langsted A; Ray KK; Tybjærg-Hansen A
    Nat Rev Cardiol; 2018 May; 15(5):261-272. PubMed ID: 29417937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?
    Halcox J; Misra A
    Metab Syndr Relat Disord; 2015 Feb; 13(1):1-21. PubMed ID: 25402738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations of the European Society of Cardiology and the European Atherosclerosis Society on Cardiovascular Disease Prevention and Management of Dyslipidemias. for the Diagnosis of Atherosclerosis and Dyslipidemia Treatment (2016): Basic S.G.].
    Bubnova MG; Kukharchuk VV
    Kardiologiia; 2017 Mar; 57(3):85-89. PubMed ID: 28762942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.